BNT162b2信使RNA新冠疫苗与突发性感音神经性听力损失风险的相关性
这项回顾性、基于人群的队列研究利用以色列最大卫生保健组织的数据,纳入2020年12月20日至2021年4月30日接种第一剂BNT162b2 mRNA新冠疫苗的2602557例16岁及以上人群,比较接种后21天内观察到的突发性感音神经性听力损失(SSNHL)病例与2018、2019年期望病例。第一剂后年龄性别加权标准化发病比为1.35(95%CI 1.09-1.65),第二剂后为1.23(95%CI 0.98-1.53),归因风险总体较小;作者认为疫苗可能与SSNHL风险升高相关,但效应量很小,需进一步研究。
要点
- 第一剂后年龄性别加权SIR为1.35(95%CI 1.09-1.65),第二剂后为1.23(95%CI 0.98-1.53)。
- 第一剂后女性16-44岁SIR为1.92(95%CI 0.98-3.43),女性65岁及以上SIR为1.68(95%CI 1.15-2.37)。
- 第二剂后男性16-44岁SIR最高,为2.45(95%CI 1.36-4.07);归因风险总体较小。
核心结论
- 本研究提示BNT162b2 mRNA新冠疫苗可能与SSNHL风险升高相关,但效应量很小;需进一步研究以确立这一可能关联。
研究设计与样本
- 回顾性、基于人群的队列研究,数据来自以色列最大卫生保健组织,时间范围为2020年12月20日至2021年5月31日。
- 纳入16岁及以上、于2020年12月20日至2021年4月30日接种第一剂、于2021年1月10日至2021年4月30日接种第二剂BNT162b2 mRNA新冠疫苗者。
- 共2602557例接种第一剂(平均[SD]年龄46.8[19.6]岁,51.5%为女性),其中2441719例(93.8%)接种第二剂。
- 主要结局为依据国际疾病分类第九版(ICD-9)编码并结合同期泼尼松发放判定的SSNHL,比较每剂后21天内观察病例与基于2018和2019年人群经验的期望病例,计算标准化发病比(SIR)与归因风险。
主要发现
- 接种第一剂后报告91例SSNHL,接种第二剂后报告79例SSNHL。
- 第一剂后年龄性别加权SIR为1.35(95%CI 1.09-1.65),第二剂后为1.23(95%CI 0.98-1.53)。
- 第一剂后女性16-44岁SIR为1.92(95%CI 0.98-3.43),女性65岁及以上SIR为1.68(95%CI 1.15-2.37)。
- 第二剂后男性16-44岁SIR最高,为2.45(95%CI 1.36-4.07)。
- 归因风险总体较小,以2019年为参考估计期望SSNHL病例数时结果相似。
临床怎么用
- 作者认为BNT162b2 mRNA新冠疫苗可能与SSNHL风险升高相关,但效应量很小,需进一步研究以确立这一可能关联。
局限性
- 原文结论指出需进一步研究以确立这一可能关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Identification of adverse events after vaccination increases awareness of vaccine-associated complications, leading to early diagnosis and treatment. Evidence remains scarce on the association between the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) and sudden sensorineural hearing loss (SSNHL). OBJECTIVE: To assess the association between the BNT162b2 mRNA COVID-19 vaccine and SSNHL. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based cohort study was performed from December 20, 2020, to May 31, 2021, using data from the largest health care organization in Israel. Patients 16 years or older who received the first vaccine dose between December 20, 2020, and April 30, 2021, and the second vaccine dose between January 10, 2021, and April 30, 2021, were included. EXPOSURES: Receipt of first and second BNT162b2 mRNA COVID-19 vaccine doses. MAIN OUTCOMES AND MEASURES: The main outcome was SSNHL based on International Classification of Diseases, Ninth Revision (ICD-9) codes in conjunction with concurrent prednisone dispensing. Observed cases of SSNHL, occurring within 21 days after each of the first and second vaccine doses, were compared with the expected cases based on the experience of the population in 2018 and 2019. Standardized incidence ratios (SIRs) and attributable risks were computed. RESULTS: Overall, 2 602 557 patients (mean [SD] age, 46.8 [19.6] years; 51.5% female) received the first dose of BNT162b2 mRNA COVID-19 vaccine, with 91 cases of SSNHL reported. Of these patients, 2 441 719 (93.8%) received the second vaccine dose, with 79 cases of SSNHL reported. The age- and sex-weighted SIRs were 1.35 (95% CI, 1.09-1.65) after the first vaccine dose and 1.23 (95% CI, 0.98-1.53) after the second vaccine dose. After the first vaccine dose, the estimated SIRs were more pronounced in female patients aged 16 to 44 years (SIR, 1.92; 95% CI, 0.98-3.43) and female patients 65 years or older (SIR, 1.68; 95% CI, 1.15-2.37). After the second vaccine dose, the highest estimated SIR was observed in male patients 16 to 44 years (SIR, 2.45; 95% CI, 1.36-4.07). The attributable risks were generally small, and the results were similar when 2019 was used as a reference to estimate the expected number of SSNHL cases. CONCLUSIONS AND RELEVANCE: This study suggests that the BNT162b2 mRNA COVID-19 vaccine might be associated with increased risk of SSNHL; however, the effect size is very small. Further studies are warranted to establish this possible association.
引用
- Yanir Y, Doweck I, Shibli R, et al. Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 35201275. doi:10.1001/jamaoto.2021.4278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。